European Anticoagulants Market 2020 Growth, COVID Impact, Trends Analysis Report 2026

European anticoagulants market is estimated to grow at a CAGR of 6.6% during the forecast period. A significant rise in the demand for NOACs has been reported in the region, which in turn, is accelerating the market growth. The use of novel oral anticoagulants (NOACs) is growing significantly in Europe as their advantages over older drugs including warfarin. NOACs have demonstrated tremendous safety and efficacy without the requirement of subsequent dose adjustment and frequent monitoring. The three NOACs that are available in the EU market include Factor Xa inhibitors Xarelto (rivaroxaban) from Bayer, Boehringer Ingelheim’s thrombin inhibitor Pradaxa (dabigatran), and Pfizer/Bristol-Myers Squibb’s Eliquis (apixaban).

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/european-anticoagulants-market

These NOACs have practical benefits over vitamin k antagonists as they do not need monitoring and complex dose titration and have fewer interactions with food and other drugs. Some common factors that encourage patients to move from vitamin K antagonists to NOACs comprise mobility problems. Vitamin K antagonists require increased visits required as well as complaints regarding dose adjustments and discomfort including pain or bruising. The interest of Daiichi Sankyo interest in the field is focused on a Factor Xa antagonist referred to as Lixiana (edoxaban). It is available on the market in Japan, Europe, and the US.

A Full Report of European Anticoagulants Market is Available at: https://www.omrglobal.com/industry-reports/european-anticoagulants-market

Scope of the European Anticoagulants Market

Market Coverage

Market number available for 2019-2026
Base year- 2019
Forecast period- 2020-2026
Segment Covered- By Type and Application
Regions Covered- UK, Germany, France, Spain, Italy, and Rest of Europe
Competitive Landscape- Johnson & Johnson Services, Inc., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH

Recent Strategic Initiatives in the European Anticoagulants Market

In July 2020, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a generic version of apixaban, an anticoagulant medicine. In the meantime, the US FDA approved a generic version of chlorzoxazone, a muscle relaxant. Apixaban is an anticoagulant that is used for the treatment and prevention of blood clots and prevention of stroke. In 2011, it was first approved for use in the EU and is sold with the brand name Eliquis by Pfizer/Bristol-Myers Squibb.
In November 2020, Boehringer Ingelheim declared the European Medicines Agency’s (EMA) Committee has adopted a positive opinion for Pradaxa (dabigatran etexilate) to treat venous thromboembolic events (VTE) and prevention of recurrent VTE in pediatric patients from birth to less than 18 years of age.

European Anticoagulants Market-Segmentation

By Type

Novel Oral Anticoagulants (NOACs)
Vitamin K Antagonist
Heparin and Low Molecular Weight Heparin (LMWH)

By Application

Pulmonary Embolism
Atrial Fibrillation/Myocardial Infarction (Heart Attack)
Deep Vein Thrombosis (DVT)
Others

European Anticoagulants Market– Segment by Country

UK
Germany
France
Spain
Italy
Rest of Europe

Company Profiles

AstraZeneca plc
Bayer AG
Boehringer Ingelheim GmbH
Bristol Myers Squibb Co.
Daiichi Sankyo Company, Ltd.
GlaxoSmithKline plc
Mylan N.V.

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-anticoagulants-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.